Diabetic Nephropathy

  • Alessia Fornoni
  • Carlos Leon
  • Leopoldo Raij


Diabetic Patient Diabetic Nephropathy Peritoneal Dialysis Renal Replacement Therapy Mesangial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    USRDS. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2005.Google Scholar
  2. 2.
    Standards of medical care in diabetes—2006. Diabetes Care 2006; 29(Suppl 1): S4–42.Google Scholar
  3. 3.
    Caramori, M.L., Fioretto, P., Mauer, M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J. Am. Soc. Nephrol. 2006; 17(2):339–352.PubMedCrossRefGoogle Scholar
  4. 4.
    Hovind, P., Tarnow, L., Rossing, P., et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: Inception cohort study. BMJ 2004; 328(7448):1105.PubMedCrossRefGoogle Scholar
  5. 5.
    Mogensen, C.E., Christensen, C.K. Predicting diabetic nephropathy in insulin-dependent patients. N. Engl. J. Med. 1984; 311(2):89–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Tognoni, G. Report on management of renal failure in Europe, XXVI, 1995. A conceptual and practical framework for interactive use of the ERA-EDTA Registry. Nephrol. Dial. Transplant 1996;11(Suppl)7:1–3.PubMedGoogle Scholar
  7. 7.
    Leon, C.A., Raij, L. Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy. J. Hypertens. 2005; 23(11):1931–1937.PubMedCrossRefGoogle Scholar
  8. 8.
    Lightstone, L., Rees, A.J., Tomson, C., Walls, J., Winearls, C.G., Feehally, J. High incidence of end-stage renal disease in Indo-Asians in the UK. Quar. J. Med. 1995; 88(3):191–195.Google Scholar
  9. 9.
    Rich, S.S. Genetics of diabetes and its complications. J. Am. Soc. Nephrol. 2006; 17(2):353–360.Google Scholar
  10. 10.
    Fioretto, P., Steffes, M.W., Barbosa, J., Rich, S.S., Miller, M.E., Mauer, M. Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes 1999; 48(4):865–869.PubMedCrossRefGoogle Scholar
  11. 11.
    Langefeld, C.D., Beck, S.R., Bowden, D.W., Rich, S.S., Wagenknecht, L.E., Freedman, B.I. Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. Am. J. Kidney Dis. 2004; 43(5):796–800.PubMedCrossRefGoogle Scholar
  12. 12.
    Susztak, K., Bottinger, E.P. Diabetic nephropathy: A frontier for personalized medicine. J. Am. Soc. Nephrol. 2006; 17(2):361–367.PubMedCrossRefGoogle Scholar
  13. 13.
    Jones, S.L., Wiseman, M.J., Viberti, G.C. Glomerular hyperfiltration as a risk factor for diabetic nephropathy: Five-year report of a prospective study. Diabetologia 1991; 34(1):59–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Caramori, M.L., Fioretto, P., Mauer, M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions. Diabetes 2003; 52(4):1036–1040.PubMedCrossRefGoogle Scholar
  15. 15.
    Klein, R., Zinman, B., Gardiner, R., et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: The Renin-Angiotensin System Study. Diabetes 2005; 54(2):527–533.PubMedCrossRefGoogle Scholar
  16. 16.
    Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995; 47(6):1703–1720.Google Scholar
  17. 17.
    Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290(16):2159–2567.Google Scholar
  18. 18.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837–853.Google Scholar
  19. 19.
    Perkins, B.A., Ficociello, L.H., Silva, K.H., Finkelstein, D.M., Warram, J.H., Krolewski, A.S. Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med. 2003; 348(23):2285–2293.PubMedCrossRefGoogle Scholar
  20. 20.
    Araki, S., Haneda, M., Sugimoto, T., et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005; 54(10):2983–2987.PubMedCrossRefGoogle Scholar
  21. 21.
    Giorgino, F., Laviola, L., Cavallo Perin, P., Solnica, B., Fuller, J., Chaturvedi, N. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: The EURODIAB Prospective Complications Study. Diabetologia 2004; 47(6):1020–1028.PubMedCrossRefGoogle Scholar
  22. 22.
    Lurbe, E., Redon, J., Kesani, A., et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N. Engl. J. Med. 2002; 347(11):797–805.PubMedCrossRefGoogle Scholar
  23. 23.
    Nelson, R.G., Pettitt, D.J., Baird, H.R., et al. Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1993; 36(10):998–1001.PubMedCrossRefGoogle Scholar
  24. 24.
    Chase, H.P., Garg, S.K., Marshall, G., et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991; 265(5):614–617.PubMedCrossRefGoogle Scholar
  25. 25.
    Baggio, B., Budakovic, A., Dalla Vestra, M., Saller, A., Bruseghin, M., Fioretto, P. Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients. J. Am. Soc. Nephrol. 2002; 13(11):2730–2736.PubMedCrossRefGoogle Scholar
  26. 26.
    Lin, J., Hu, F.B., Rimm, E.B., Rifai, N., Curhan, G.C. The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int. 2006; 69(2):336–342.PubMedCrossRefGoogle Scholar
  27. 27.
    Mogensen, C.E., Schmitz, A., Christensen, C.K. Comparative renal pathophysiology relevant to IDDM and NIDDM patients. Diabetes Metab. Rev. 1988; 4(5):453–483.PubMedGoogle Scholar
  28. 28.
    Kramer, H.J., Nguyen, Q.D., Curhan, G., Hsu, C.Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289(24):3273–3277.PubMedCrossRefGoogle Scholar
  29. 29.
    Eknoyan, G., Hostetter, T., Bakris, G.L., et al. Proteinuria and other markers of chronic kidney disease: A position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am. J. Kidney Dis. 2003; 42(4):617–622.PubMedCrossRefGoogle Scholar
  30. 30.
    K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002; 39(2 Suppl 1):S1–266.Google Scholar
  31. 31.
    Striker LJS, G., D’ Agati, V. The Renal Biopsy, 3rd ed. Philadelphia: W.B. Saunders Company. 1997.Google Scholar
  32. 32.
    Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005; 54(6):1615–1625.PubMedCrossRefGoogle Scholar
  33. 33.
    Ziyadeh, F.N., Sharma, K., Ericksen, M., Wolf, G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J. Clin. Invest. 1994; 93(2):536–542.PubMedGoogle Scholar
  34. 34.
    Williams, M.E., Tuttle, K.R. The next generation of diabetic nephropathy therapies: An update. Adv. Chronic Kidney Dis. 2005; 12(2):212–222.PubMedCrossRefGoogle Scholar
  35. 35.
    Fornoni, A., Lenz, O., Striker, L.J., Striker, G.E. Glucose induces clonal selection and reversible dinucleotide repeat expansion in mesangial cells isolated from glomerulosclerosis-prone mice. Diabetes 2003; 52(10):2594–2602.PubMedCrossRefGoogle Scholar
  36. 36.
    Gnudi, L., Viberti, G., Raij, L., et al. GLUT-1 overexpression: Link between hemodynamic and metabolic factors in glomerular injury? Hypertension 2003; 42(1):19–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Carmines, P.K., Ohishi, K., Ikenaga, H. Functional impairment of renal afferent arteriolar voltage-gated calcium channels in rats with diabetes mellitus. J. Clin. Invest. 1996; 98(11):2564–2571.PubMedCrossRefGoogle Scholar
  38. 38.
    Galkina, E., Ley, K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J. Am. Soc. Nephrol. 2006; 17(2):368–377.PubMedCrossRefGoogle Scholar
  39. 39.
    Lewis, E.J., Hunsicker, L.G., Bain, R.P., Rohde, R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 1993; 329(20):1456–1462.PubMedCrossRefGoogle Scholar
  40. 40.
    Bakris, G.L., Williams, M., Dworkin, L., et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. 2000; 36(3):646–661.PubMedGoogle Scholar
  41. 41.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200):253–259.Google Scholar
  42. 42.
    Parving, H.H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S., Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345(12):870–878.PubMedCrossRefGoogle Scholar
  43. 43.
    Brenner, B.M., Cooper, M.E., de Zeeuw, D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345(12):861–869.PubMedCrossRefGoogle Scholar
  44. 44.
    Lewis, E.J., Hunsicker, L.G., Clarke, W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345(12):851–860.PubMedCrossRefGoogle Scholar
  45. 45.
    Hou, F.F., Zhang, X., Zhang, G.H., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 2006; 354(2):131–140.PubMedCrossRefGoogle Scholar
  46. 46.
    Barnett, A.H., Bain, S.C., Bouter, P., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 2004; 351(19):1952–1961.PubMedCrossRefGoogle Scholar
  47. 47.
    Chobanian, A.V., Bakris, G.L., Black, H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6):1206–1252.PubMedCrossRefGoogle Scholar
  48. 48.
    Ruggenenti, P., Fassi, A., Ilieva, A.P., et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004; 351(19):1941–1951.PubMedCrossRefGoogle Scholar
  49. 49.
    Gaede, P., Vedel, P., Larsen, N., Jensen, G.V., Parving, H.H., Pedersen, O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003; 348(5):383–393.PubMedCrossRefGoogle Scholar
  50. 50.
    Brown, A.F., Mangione, C.M., Saliba, D., Sarkisian, C.A. Guidelines for improving the care of the older person with diabetes mellitus. J. Am. Geriatr. Soc. 2003; 51(5 Suppl Guidelines):S265–280.Google Scholar
  51. 51.
    Wolfe, R.A., Port, F.K., Hawthorne, V.M., Guire, K.E. A comparison of survival among dialytic therapies of choice: In-center hemodialysis versus continuous ambulatory peritoneal dialysis at home. Am. J. Kidney Dis. 1990; 15(5):433–440.PubMedGoogle Scholar
  52. 52.
    Held, P.J., Port, F.K., Turenne, M.N., Gaylin, D.S., Hamburger, R.J., Wolfe, R.A. Continuous ambulatory peritoneal dialysis and hemodialysis: Comparison of patient mortality with adjustment for comorbid conditions. Kidney Int. 1994; 45(4):1163–1169.PubMedCrossRefGoogle Scholar
  53. 53.
    Vonesh, E.F., Snyder, J.J., Foley, R.N., Collins, A.J. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int. 2004; 66(6):2389–2401.PubMedCrossRefGoogle Scholar
  54. 54.
    Brunner, F.P., Selwood, N.H. Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. Kidney Int. Suppl. 1992; 38:S4–15.PubMedGoogle Scholar
  55. 55.
    Konner, K., Hulbert-Shearon, T.E., Roys, E.C., Port, F.K. Tailoring the initial vascular access for dialysis patients. Kidney Int. 2002; 62(1):329–338.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Alessia Fornoni
  • Carlos Leon
  • Leopoldo Raij

There are no affiliations available

Personalised recommendations